




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 6 : C07D 307/58, 309/32, C07C 311/15, 309/73, A61K 31/34, 31/365, 31/18</p>	<p>A1</p>	<p>(11) International Publication Number: WO 95/18799</p> <p>(43) International Publication Date: 13 July 1995 (13.07.95)</p>
<p>(21) International Application Number: PCT/CA94/00688</p> <p>(22) International Filing Date: 19 December 1994 (19.12.94)</p> <p>(30) Priority Data: 179,467 10 January 1994 (10.01.94) US</p> <p>(71) Applicant: MERCK FROSST CANADA INC. [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA).</p> <p>(72) Inventors: DUCHARME, Yves; 4501 Kensington, Montreal, Quebec H4B 2W6 (CA). GAUTHIER, Jacques, Yves; Apartment 2, 540 Odette Oligny, Laval, Quebec H7N 5Z4 (CA). PRASIT, Petpiboon; 177 Argyle Drive, Kirkland, Quebec H9H 5A6 (CA). LEBLANC, Yves; 8 Lafford, Kirkland, Quebec H9J 3Y3 (CA). WANG, Zhaoyin; 13199 Edison Crescent, Pierrefonds, Quebec H8Z 1Y5 (CA). LEGER, Serge; 51 Lamarche, Dollard Des Ormeaux, Quebec H9B 3E5 (CA). THERIEN, Michel; 944 21st Avenue, Laval, Quebec H7R 2R2 (CA).</p> <p>(74) Agent: MURPHY, Kevin, P.; Swabey, Ogilvy, Renault, Suite 1600, 1981 McGill College, Montreal, Quebec H3A 2Y3 (CA).</p>	<p>(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, UZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: PHENYL HETEROCYCLES AS COX-2 INHIBITORS</p> <div style="text-align: center; margin: 20px 0;">  <p style="margin-top: 10px;">(I)</p> </div>		
<p>(57) Abstract</p> <p>The invention encompasses the novel compound of Formula (I) useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula (I).</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

TITLE OF THE INVENTION

PHENYL HETEROCYCLES AS COX-2 INHIBITORS

BACKGROUND OF THE INVENTION

5 This invention relates to compounds and pharmaceutical compositions for the treatment of cyclooxygenase mediated diseases and methods of treatment thereof.


 Non-steroidal, antiinflammatory drugs exert most of their antiinflammatory, analgesic and antipyretic activity and inhibit hormone-
10 induced uterine contractions and certain types of cancer growth through inhibition of prostaglandin G/H synthase, also known as cyclooxygenase. Up until recently, only one form of cyclooxygenase had been characterized, this corresponding to cyclooxygenase-1 or the constitutive enzyme, as originally identified in bovine seminal vesicles. Recently the
15 gene for a second inducible form of cyclooxygenase (cyclooxygenase-2) has been cloned, sequenced and characterized from chicken, murine and human sources. This enzyme is distinct from the cyclooxygenase-1 which has now also been cloned, sequenced and characterized from sheep, murine and human sources. The second form of cyclooxygenase,
20 cyclooxygenase-2, is rapidly and readily inducible by a number of agents including mitogens, endotoxin, hormones, cytokines and growth factors. As prostaglandins have both physiological and pathological roles, we have concluded that the constitutive enzyme, cyclooxygenase-1, is responsible, in large part, for endogenous basal release of prostaglandins
25 and hence is important in their physiological functions such as the maintenance of gastrointestinal integrity and renal blood flow. In contrast, we have concluded that the inducible form, cyclooxygenase-2, is mainly responsible for the pathological effects of prostaglandins where rapid induction of the enzyme would occur in response to such agents as
30 inflammatory agents, hormones, growth factors, and cytokines. Thus, a selective inhibitor of cyclooxygenase-2 will have similar antiinflammatory, antipyretic and analgesic properties to a conventional non-steroidal antiinflammatory drug, and in addition would inhibit hormone-induced uterine contractions and have potential anti-cancer

- 2 -

effects, but will have a diminished ability to induce some of the mechanism-based side effects. In particular, such a compound should have a reduced potential for gastrointestinal toxicity, a reduced potential for renal side effects, a reduced effect on bleeding times and possibly a lessened ability to induce asthma attacks in aspirin-sensitive asthmatic subjects.

SUMMARY OF THE INVENTION

The invention encompasses novel compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.



The invention also encompasses certain pharmaceutical compositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I.


- 3 -

DETAILED DESCRIPTION OF THE INVENTION

The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases

5

10



I

or pharmaceutically acceptable salts thereof wherein:

15 X-Y-Z-is selected from the group consisting of:

- (a) -CH₂CH₂CH₂-,
- (b) -C(O)CH₂CH₂-,
- (c) -CH₂CH₂C(O)-,
- (d) -CR⁵(R^{5'})-O-C(O)-,
- 20 (e) -C(O)-O-CR⁵(R^{5'})-,
- (f) -CH₂-NR³-CH₂-,
- (g) -CR⁵(R^{5'})-NR³-C(O)-,
- (h) -CR⁴=CR^{4'}-S-,
- (i) -S-CR⁴=CR^{4'}-,
- 25 (j) -S-N=CH-,
- (k) -CH=N-S-,
- (l) -N=CR⁴-O-,
- (m) -O-CR⁴=N-,
- (n) -N=CR⁴-NH-,
- 30 (o) -N=CR⁴-S-, and
- (p) -S-CR⁴=N-;
- (q) -C(O)-NR³-CR⁵(R^{5'})-,
- (r) -R³N-CH=CH-, provided R¹ is not -S(O)₂Me,
- (s) -CH=CH-NR³-, provided R¹ is not -S(O)₂Me,

- 4 -

when side b is a double bond, and sides a and c are single bonds; and

X-Y-Z is selected from the group consisting of:

- (a) =CH-O-CH=, and
- 5 (b) =CH-NR³-CH=,
- (c) =N-S-CH=,
- (d) =CH-S-N=,
- (e) =N-O-CH=,
- (f) =CH-O-N=,
- 10 (g) =N-S-N=,
- (h) =N-O-N=,

when sides a and c are double bonds and side b is a single bond;

R¹ is selected from the group consisting of:

- (a) S(O)₂CH₃,
- 15 (b) S(O)₂NH₂,
- (c) S(O)₂NHC(O)CF₃,
- (d) S(O)(NH)CH₃,
- (e) S(O)(NH)NH₂,
- (f) S(O)(NH)NHC(O)CF₃,
- 20 (g) P(O)(CH₃)OH, and
- (h) P(O)(CH₃)NH₂,

R² is selected from the group consisting of:

- (a) C₁₋₆alkyl,
- (b) C₃, C₄, C₅, C₆, and C₇, cycloalkyl,
- 25 (c) mono-, di- or tri-substituted phenyl or naphthyl wherein the substituent is selected from the group consisting of:
 - (1) hydrogen,
 - (2) halo,
 - (3) C₁₋₆alkoxy,
 - 30 (4) C₁₋₆alkylthio,
 - (5) CN,
 - (6) CF₃,
 - (7) C₁₋₆alkyl,
 - (8) N₃,

- 5 -

- (9) $-\text{CO}_2\text{H}$,
(10) $-\text{CO}_2\text{-C}_{1-4}\text{alkyl}$,
(11) $-\text{C}(\text{R}^5)(\text{R}^6)\text{-OH}$,
(12) $-\text{C}(\text{R}^5)(\text{R}^6)\text{-O-C}_{1-4}\text{alkyl}$, and
5 (13) $-\text{C}_{1-6}\text{alkyl-CO}_2\text{-R}^5$;
- (d) mono-, di- or tri-substituted heteroaryl wherein the heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one hetero atom which is S, O, or N, and optionally 1, 2, or 3 additionally N atoms; or
10 the heteroaryl is a monocyclic ring of 6 atoms, said ring having one hetero atom which is N, and optionally 1, 2, 3, or 4 additional N atoms; said substituents are selected from the group consisting of:
- (1) hydrogen,
15 (2) halo, including fluoro, chloro, bromo and iodo,
(3) $\text{C}_{1-6}\text{alkyl}$,
(4) $\text{C}_{1-6}\text{alkoxy}$,
(5) $\text{C}_{1-6}\text{alkylthio}$,
(6) CN ,
20 (7) CF_3 ,
(8) N_3 ,
(9) $-\text{C}(\text{R}^5)(\text{R}^6)\text{-OH}$, and
(10) $-\text{C}(\text{R}^5)(\text{R}^6)\text{-O-C}_{1-4}\text{alkyl}$;
- (e) benzoheteroaryl which includes the benzo fused analogs of
25 (d);
- R^3 is selected from the group consisting of:
- (a) hydrogen,
(b) CF_3 ,
(c) CN ,
30 (d) $\text{C}_{1-6}\text{alkyl}$,
(e) $\text{hydroxyC}_{1-6}\text{alkyl}$,
(f) $-\text{C}(\text{O})\text{-C}_{1-6}\text{alkyl}$,
(g) optionally substituted
(1) $-\text{C}_{1-5}\text{ alkyl-Q}$,

- 6 -

- (2) -C₁₋₃alkyl-O-C₁₋₃alkyl-Q,
- (3) -C₁₋₃alkyl-S-C₁₋₃alkyl-Q,
- (4) -C₁₋₅ alkyl-O-Q, or
- (5) -C₁₋₅ alkyl-S-Q,

5 wherein the substituent resides on the alkyl and the substituent is C₁₋₃alkyl;

(h) -Q;

R⁴ and R^{4'} are each independently selected from the group consisting of:

- (a) hydrogen,
- 10 (b) CF₃,
- (c) CN,
- (d) C₁₋₆alkyl,
- (e) -Q,
- (f) -O-Q;
- 15 (g) -S-Q, and
- (h) optionally substituted
 - (1) -C₁₋₅ alkyl-Q,
 - (2) -O-C₁₋₅ alkyl-Q,
 - (3) -S-C₁₋₅ alkyl-Q,
 - 20 (4) -C₁₋₃alkyl-O-C₁₋₃alkyl-Q,
 - (5) -C₁₋₃alkyl-S-C₁₋₃alkyl-Q,
 - (6) -C₁₋₅ alkyl-O-Q,
 - (7) -C₁₋₅ alkyl-S-Q,

25 wherein the substituent resides on the alkyl and the substituent is C₁₋₃alkyl, and

R⁵, R^{5'}, R⁶, R⁷ and R⁸ are each independently selected from the group consisting of:

- (a) hydrogen,
- (b) C₁₋₆alkyl,
- 30 or R⁵ and R⁶ or R⁷ and R⁸ together with the carbon to which they are attached form a saturated monocyclic carbon ring of 3, 4, 5, 6 or 7 atoms;

- 7 -

Q is CO₂H, CO₂-C₁₋₄alkyl, tetrazolyl-5-yl, C(R⁷)(R⁸)(OH), or C(R⁷)(R⁸)(O-C₁₋₄alkyl);

5 provided that when X-Y-Z is -S-CR⁴=CR^{4'}, then R⁴ and R^{4'} are other than CF₃.

One Class within this embodiment are the compounds of Formula I



I

or pharmaceutically acceptable salts thereof wherein:

X-Y-Z- is selected from the group consisting of -C(O)-O-CR⁵(R^{5'})- when side b is a double bond, and sides a and c are single bonds; and

20 R¹ is selected from the group consisting of:

- (a) S(O)₂CH₃,
- (b) S(O)₂NH₂,

R² is selected from the group consisting of:

- (a) C₁₋₆alkyl,
- 25 (b) C₃, C₄, C₅, C₆, and C₇, cycloalkyl,
- (c) heteroaryl,
- (d) benzoheteroaryl,
- (e) mono- or di-substituted phenyl wherein the substituent is selected from the group consisting of:

- 30 (1) hydrogen,
- (2) halo,
- (3) C₁₋₆alkoxy,
- (4) C₁₋₆alkylthio,
- (5) CN,

- 8 -

- 5
- (6) CF₃,
 - (7) C₁₋₆alkyl,
 - (8) N₃,
 - (9) -CO₂H,
 - (10) -CO₂-C₁₋₄alkyl,
 - (11) -C(R⁵)(R⁶)-OH,
 - (12) -C(R⁵)(R⁶)-O-C₁₋₄alkyl, and
 - (13) -C₁₋₆alkyl-CO₂-R⁵;

10 R⁵, R^{5'} and R⁶ are each independently selected from the group consisting of:

- (a) hydrogen,
 - (b) C₁₋₆alkyl,
- or R⁵ and R⁶ together with the carbon to which they are attached form a saturated monocyclic carbon ring of 3, 4, 5, 6 or 7 atoms.
- 15

For purposes of this specification alkyl is defined to include linear, branched, and cyclic structures, with C₁₋₆alkyl including including methyl, ethyl, propyl, 2-propyl, s- and t-butyl, butyl, pentyl, hexyl, 1,1-dimethylethyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Similarly, C₁₋₆alkoxy is intended to include alkoxy groups of from 1 to 6 carbon atoms of a straight, branched, or cyclic configuration. Examples of lower alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy, and the like. Likewise, C₁₋₆alkylthio is intended to include alkylthio groups of from 1 to 6 carbon atoms of a straight, branched or cyclic configuration. Examples of lower alkylthio groups include methylthio, propylthio, isopropylthio, cycloheptylthio, etc. By way of illustration, the propylthio group signifies -SCH₂CH₂CH₃.

20

25

30 Heteroaryl includes furan, thiophene, pyrrole, isoxazole, isothiazole, pyrazole, oxazole, thiazole, imidazole, 1,2,3-oxadiazole, 1,2,3-thiadiazole, 1,2,3-triazole, 1,3,4-oxadiazole, 1,3,4-thiadiazole, 1,3,4-triazole, 1,2,5-oxadiazole, 1,2,5-thiadiazole, pyridine, pyridazine,

- 9 -

pyrimidine, pyrazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,4,5-tetrazine, and the like.

Benzoheteroaryl includes the above heteroaryl rings to which it is possible to fuse a benzene ring.

5

Exemplifying the invention are:

10

15

20

25

30

- (a) 3-(4-(Aminosulfonyl)phenyl)-2-(4-fluorophenyl)-5-(2-hydroxy-2-propyl)thiophene,
- (b) 3-(4-(Aminosulfonyl)phenyl)-2-(4-fluorophenyl)thiophene,
- (c) 3-(4-(Aminosulfonyl)phenyl)-2-(4-fluorophenyl)-5-(2-propyl)thiophene,
- (d) 3-(4-(Aminosulfonyl)phenyl)-2-cyclohexylthiophene,
- (e) 5-(4-Carboxyphenyl)-4-(4-(methylsulfonyl)phenyl)-thiophene-2-carboxylic acid,
- (f) 4-(4-Fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)phenyl)-thiazole,
- (g) 2-(4-Fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-2-cyclopenten-1-one
- (h) 4-(4-(Methylsulfonyl)phenyl)-5-(4-fluorophenyl)-isothiazole,
- (i) 3-(4-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (j) 3-(4-Fluorophenyl)-4-(4-(aminosulfonyl)phenyl)-2-(5H)-furanone,
- (k) 3-(4-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)furan,
- (l) 5,5-Dimethyl-3-(4-fluorophenyl)-4-(4-methylsulfonyl)-phenyl)-2-(5H)-furanone,
- (m) 2-(4-(Aminosulfonyl)phenyl)-3-(4-fluorophenyl)thiophene, and
- (n) 3-(4-(Trifluoroacetylaminosulfonyl)phenyl)-2-(4-fluorophenyl)thiophene,
- (o) 3-(3-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (p) 5,5-Dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)-phenyl)-2-(5H)-furanone,

- 10 -

- 5 (q) 5,5-Dimethyl-3-(3-chlorophenyl)-4-(4-methylsulfonyl)-phenyl)-2-(5*H*)-furanone,
(r) 3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-furanone,
(s) 3-(3,4-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-furanone,
(t) 5,5-Dimethyl-3-(3,4-difluorophenyl)-4-(4-methylsulfonyl)-phenyl)-2-(5*H*)-furanone,
10 (u) 5,5-Dimethyl-3-(3,4-dichlorophenyl)-4-(4-methylsulfonyl)-phenyl)-2-(5*H*)-furanone,
(v) 5,5-Dimethyl-3-(4-chlorophenyl)-4-(4-methylsulfonyl)-phenyl)-2-(5*H*)-furanone,
(w) 3-(2-Naphylhyl)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-furanone,
15 (x) 5,5-Dimethyl-3-(2-naphylhyl)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-furanone,
(y) 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-furanone.

20 Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers. The present invention is meant to comprehend such possible diastereomers as well as their racemic and resolved, enantiomerically pure forms and pharmaceutically acceptable salts thereof.

25 Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers.

In a second embodiment, the invention encompasses pharmaceutical compositions for inhibiting cyclooxygenase and for
30 treating cyclooxygenase mediated diseases as disclosed herein comprising a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of compound of Formula I as described above.

- 11 -

Within this embodiment the invention encompasses pharmaceutical compositions for inhibiting cyclooxygenase-2 and for treating cyclooxygenase-2 mediated diseases as disclosed herein comprising a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of compound of Formula I as described above.

In a third embodiment, the invention encompasses a method of inhibiting cyclooxygenase and treating cyclooxygenase mediated diseases, advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1 as disclosed herein comprising: administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I as disclosed herein.

For purposes of this specification a compound is said to selectively inhibit COX-2 in preference to COX-1 if the ratio of the IC₅₀ concentration for COX-1 inhibition to COX-2 inhibition is 100 or greater.

The pharmaceutical compositions of the present invention comprise a compound of Formula I as an active ingredient or a pharmaceutically acceptable salt, thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine,

- 12 -

methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.

5 It will be understood that in the discussion of methods of treatment which follows, references to the compounds of Formula I are meant to also include the pharmaceutically acceptable salts.

10 The Compound of Formula I is useful for the relief of pain, fever and inflammation of a variety of conditions including rheumatic fever, symptoms associated with influenza or other viral infections, common cold, low back and neck pain, dysmenorrhea, headache, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns, injuries, following surgical and dental procedures. In addition, such a compound may
15 inhibit cellular neoplastic transformations and metastatic tumor growth and hence can be used in the treatment of cancer. Compounds of Formula I may also be useful for the treatment of dementia including pre-senile and senile dementia, and in particular, dementia associated with Alzheimer Disease (i.e., Alzheimer's dementia).

20 Compounds of Formula I will also inhibit prostanoid-induced smooth muscle contraction by preventing the synthesis of contractile prostanoids and hence may be of use in the treatment of dysmenorrhea, premature labor and asthma.

25 By virtue of its high cyclooxygenase-2 (COX-2) activity and/or its selectivity for cyclooxygenase-2 over cyclooxygenase-1 (COX-1) as defined above, compounds of Formula I will prove useful as an alternative to conventional non-steroidal antiinflammatory drugs (NSAID'S) particularly where such non-steroidal antiinflammatory drugs may be contra-indicated such as in patients with peptic ulcers, gastritis,
30 regional enteritis, ulcerative colitis, diverticulitis or with a recurrent history of gastrointestinal lesions; GI bleeding, coagulation disorders including anemia such as hypoprothrombinemia, haemophilia or other bleeding problems (including those relating to reduced or impaired platelet function); kidney disease (e.g., impaired renal function); those

- 13 -

prior to surgery or taking anticoagulants; and those susceptible to NSAID induced asthma.

Similarly, compounds of Formula I, will be useful as a partial or complete substitute for conventional NSAID'S in preparations wherein they are presently co-administered with other agents or ingredients. Thus in further aspects, the invention encompasses pharmaceutical compositions for treating cyclooxygenase-2 mediated diseases as defined above comprising a non-toxic therapeutically effective amount of the compound of Formula I as defined above and one or more ingredients such as another pain reliever including acetaminophen or phenacetin; a potentiator including caffeine; an H2-antagonist, aluminum or magnesium hydroxide, simethicone, a decongestant including phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxyephedrine; an antiitussive including codeine, hydrocodone, caramiphen, carbetapentane, or dextramethorphan; a diuretic; a sedating or non-sedating antihistamine. In addition the invention encompasses a method of treating cyclooxygenase mediated diseases comprising: administration to a patient in need of such treatment a non-toxic therapeutically effect amount of the compound of Formula I, optionally co-administered with one or more of such ingredients as listed immediately above.

Compounds of the present invention are inhibitors of cyclooxygenase-2 and are thereby useful in the treatment of cyclooxygenase-2 mediated diseases as enumerated above. This activity is illustrated by their ability to selectively inhibit cyclooxygenase-2 over cyclooxygenase-1. Accordingly, in one assay, the ability of the compounds of this invention to treat cyclooxygenase mediated diseases can be demonstrated by measuring the amount of prostaglandin E₂ (PGE₂) synthesized in the presence of arachidonic acid, cyclooxygenase-1 or cyclooxygenase-2 and a compound of Formula I. The IC₅₀ values represent the concentration of inhibitor required to return PGE₂ synthesis to 50% of that obtained as compared to the uninhibited control. Illustrating this aspect, we have found that the Compounds of the

- 14 -

Examples are more than 100 times more effective in inhibiting COX-2 than they are at inhibiting COX-1. In addition they all have a COX-2 IC₅₀ of 1 nM to 1 μ M. By way of comparison, Ibuprofen has an IC₅₀ for COX-2 of 1 μ M, and Indomethacin has an IC₅₀ for COX-2 of approximately 100 nM. For the treatment of any of these cyclooxygenase mediated diseases, compounds of Formula I may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle sheep, dogs, cats, etc., the compound of the invention is effective in the treatment of humans.

As indicated above, pharmaceutical compositions for treating cyclooxygenase-2 mediated diseases as defined may optionally include one or more ingredients as listed above.

The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic

- 15 -

acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Patent 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.

Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethyl-cellulose, methylcellulose, hydroxy-propylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example, polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example, arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The

- 16 -

oily suspensions may contain a thickening agent, for example, beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example, sweetening, flavoring and coloring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example, liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, for example, soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example, polyoxy-ethylene sorbitan monooleate. The emulsions may also contain sweetening and flavouring agents.

Syrups and elixirs may be formulated with sweetening agents, for example, glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In

- 17 -

addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

5 Compounds of Formula I may also be administered in the form of a suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the
10 drug. Such materials are cocoa butter and polyethylene glycols.

 For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compound of Formula I are employed. (For purposes of this application, topical application shall include mouth washes and gargles.)
15

 Dosage levels of the order of from about 0.01 mg to about 140 mg/kg of body weight per day are useful in the treatment of the above-indicated conditions, or alternatively about 0.5 mg to about 7 g per patient per day. For example, inflammation may be effectively treated by
20 the administration of from about 0.01 to 50 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per patient per day.

 The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending
25 upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration of humans may contain from 0.5 mg to 5 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Dosage unit
30 forms will generally contain between from about 1 mg to about 500 mg of an active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.

 It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including

- 18 -

the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

5 Methods of Synthesis

 The compounds of the present invention can be prepared according to the following methods.

Method A:


10 The β -chlorovinylaldehyde III can be obtained from the ketone II and the Vilsmeier reagent (DMF-POCl₃) using the general method described by Weissenfels (*Z. Chem.* 1966, 6, 471). The thiophene compound IV is obtained from III using the general method described by Weissenfels (*Z. Chem.* 1973, 13, 57). The thiol compound
15 V can be obtained after oxidation of compound IV ($R^a = -SMe$) with one equivalent of m-CPBA followed by treatment of the resulting sulfoxide with TFAA at reflux. The sulfonamide group (VI) can then be formed by the method of Kharash (*J. Amer. Chem. Soc.* 1951, 73, 3240). The hydrolysis of compound VI and decarboxylation with Cu bronze in
20 quinoline provides compound VII. Compound VII ($R^4 = H$) can be treated with halogenating agent such as bromine in acetic acid to allow the preparation of the 5-bromothiophene (VII, $R^4 = Br$). When it is desired to have a nitrile group at C-5, this can be accomplished from VI via amide formation using the Weinreb methodology (*Tetrahedron Letters*, 1977, 4171) followed by dehydration with TFAA. The CF₃
25 group can be introduced at C-5 of VII via the method of Girard (*J. Org. Chem.* 1983, 48, 3220).

 The introduction of an alkyl group at C-5 can be achieved via a Friedel-Crafts reaction on VII ($R^4 = H$) and an acyl chloride, Cl-CO-lower alkyl and a catalyst such as TiCl₄, followed by reduction. For
30 $R^4 = Me$, this can be achieved from the ester ($R^4 = CO_2Me$) via a DIBAL-H reduction followed by deoxygenation using the method of Lau (*J. Org. Chem.* 1986, 51, 3038). Tertiary alcohols ($R^4 = -C(CH_3)_2OH$) can be obtained from VI and MeMgBr. These tertiary alcohols can also be

- 19 -





deoxygenated using the method of Lau. Similarly, the thiophene IX can be prepared from ketone VIII.

METHOD A



- 20 -

METHOD A CONT'D



25


Method B:

Ketone X can be converted to the thiophene compound XI using general methods already described in Method A. The thiophene XII can be prepared by metallation of XI with n-BuLi, quenching with methyl phosphonic dichloride and addition of water or ammonia ($X' = OH$ or NH_2). Similarly, the other regioisomer XIV can be prepared from ketone XIII.

30

- 21 -

METHOD B



25


Method C:

Bromination of ketone II gives the α -bromoketone XV which is then converted to the thiazole XVI after treatment with a thioamide. Similarly, ketone VIII can be converted to thiazole XVII.

30

- 22 -


METHOD C

**Method D:**

Ketone XV can be converted to the imidazole compound XVIII after treatment with formamide using the preparation of Brederick et al, Chem. Ber. 1953, p. 88.

- 23 -


METHOD D

Method E:

10 Pyrole compound XX can be obtained from diketone XIX using the general procedures of Friedman *et al.*, *J. Org. Chem.* 1965, 30, p. 854, K. Dimroth *et al.*, *Ber.* 1956, 56, 2602, K. Dimroth *et al.*, *Ann.* 1961, 634, 102. The free NH of the pyrole can be acylated with Cl-CO-lower alkyl in the presence of a base such as Et₃N. Also alkylated

15 products can be prepared using alkyl halides as reagents with a base such as NaH.

METHOD E



- 24 -

Method F:

The compounds of type XXV can be prepared from readily available 4-substituted phenylacetyl chlorides XXIa. Reaction of di(3-butenyl)cadmium with a 4-substituted phenylacetyl chloride provides ketone XXI. Ozonolysis of XXI affords keto aldehyde XXIb which is cyclized by base to give cyclopentenone XXII. Addition of arylmagnesium bromide or aryllithium to XXII gives allylic alcohol XXIV. Oxidation of XXIV with pyridinium chlorochromate affords the desired 2,3-disubstituted cyclopentenone XXV. For preparation of compound XXV ($R^1=SO_2Me$), 4-methylthiophenyllithium is used followed by oxidation with the magnesium salt of monoperoxyphthalic acid (MMPP) or m-chloroperoxybenzoic acid (mCPBA) to introduce the required methylsulfonyl group in XXV.

15


20

25

30

- 25 -

METHOD F

Method G:


The sequence of Method G is the same as in Method F except R¹ containing acid chloride is used as starting material. R² is

- 26 -


introduced at a later stage via a carbonyl addition reaction, followed by PCC oxidation.

METHOD G

5




10



15

20



25

Method H:


30

The 4,5-disubstituted isothiazoles and isothiazol-3(2H)-one-1,1-dioxides can be prepared by the general method described by B. Schulze *et al.*, *Helvetica Chimica Acta*, 1991, 74, 1059. Thus, aldehyde III ($R^a = \text{SO}_2\text{Me}$) or XXVII is treated with excess NH_4SCN in refluxing acetone to provide the corresponding 4,5-disubstituted isothiazoles XXX

- 27 -

and XXVIII, oxidation of which with hydrogen peroxide yields XXXI and XXIX.

METHOD H




- 28 -

Method I:

An appropriately substituted aryl bromomethyl ketone is reacted with an appropriately substituted aryl acetic acid in a solvent such as acetonitrile in the presence of a base such as triethylamine and then treated with 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) to afford either the lactone XXXIII or XXXV.

METHOD I



(R² is a mono- or disubstituted phenyl or
a mono- or disubstituted heteroaryl)



Method J:

Either of the lactones XXXIII or XXXV in a solvent such as THF is reacted with a reducing agent such as diisobutyl aluminium hydride or lithium borohydride at -78°C, to yield the furan XXXVI.

- 29 -

METHOD J

5

XXXIII
or
XXXV

XXXVI

10

Method K:

The preparation of lactams XXXVII and XXXIX can be achieved by the same reaction as described in Method I, except an appropriate amide is used.

15


20

25

30

- 30 -

METHOD K


Method L:

25 Methyl 2-hydroxy isobutyrate is silylated with TMSCl to give the TMS ether XXXXI, which is treated with 4-methylthiophenyl-lithium to provide ketone XXXXII. Desilylation followed by acylation yields keto-ester XXXXIV, which can be cyclized to lactone XXXXV by base catalysis. Oxidation of XXXXV with MMPP or mCPBA affords the desired product XXXXVI.

30


- 31 -

METHOD L



- 32 -

METHOD M



10

An alternative preparation of the hydroxy ketone XXXXIII is the oxidation of the known (*J. Org. Chem.* 1991 56, 5955-8; *Sulfur Lett.* 1991, 12, 123-32) ketone XXXXIV. A mixture of XXXXIV, aqueous base, such as NaOH, organic solvents such as carbon tetrachloride/toluene and a phase transfer catalyst such as ALIQUAT 336 is stirred in air at room temperature to provide XXXXIII. Compound XXXXIII is also described in U.S. 4,321,118 and *Org. Coat.* 1986, 6, 175-95.

20 Representative Compounds







Tables I and II illustrate compounds of Formula I.

25

30





- 33 -

Table I

		Example	Method
5		1	A
10		2	A
15		3	A
20		4	A
25		5	A
30		6	C

- 34 -

Table I (continued)





		Example	Method
5		7	F
10		8	H
15		9	I
20		10	I

25

30






- 35 -

Table I (continued)

	Example	Method
5		
		11 J
10		
		12 L
15		
20		
		13 A
25		
		14 A
30		

- 36 -






Table I (continued)

		Example	Method
5		15	I
10		16	I
15		17	I
20		18	I
25		19	I

30






- 37 -

Table I (continued)

		Example	Method
5		20	I
10		21	I
15		22	I
20		23	I
25		24	I

30






Table I (continued)

		Example	Method
5		25	I
10		26	I
15		27	I
20		28	I
25		29	I

30

- 39 -

Table I (continued)

		Example	Method
5		30	I
10		31	I
15		32	I
20		33	I
25		34	I
30			

- 40 -

Table I (continued)






		Example	Method
5		35	I
10		36	I
15		37	I
20		38	I
25		39	I
30			

Table I (continued)






		Example	Method
5		40	I
10		41	I
15		42	I
20		43	I
25		44	I
30			

Table I (continued)















		Example	Method
5		45	I
10		46	I
15		47	I
20		48	I
25		49	I
30			

Table I (continued)

		Example	Method
5		50	I
10		51	I
15		52	I
20		53	I
25		54	I
30			



- 44 -

Table I (continued)


	Example	Method
5		55 H
10		56 L + M
15		57 L + M
20		
25		58 L + M
30		

- 45 -

Table I (continued)

	Example	Method	
5			
		59	L + M
10			
		60	L + M
15			
20			
25			
30			

- 46 -

Table II

- 47 -


Table II (continued)




Table II (continued)

Table II (continued)


5




10




15




20



25




30




- 50 -

Table II (continued)


5




10



15



20



25


30

- 51 -

Table II (continued)


5

10




15

20



25

30



- 52 -


Table II (continued)


Table II (continued)


Table II (concluded)


Table II (concluded)



Table II (concluded)

Table II (concluded)

- 58 -

Assays for Determining Biological Activity

The compound of Formula I can be tested using the following assays to determine their cyclooxygenase-2 inhibiting activity.

5 Inhibition of Cyclooxygenase Activity

Compounds were tested as inhibitors of cyclooxygenase activity in whole cell and microsomal cyclooxygenase assays. Both of these assays measured prostaglandin E₂ (PGE₂) synthesis in response to arachidonic acid, using a radioimmunoassay. Cells used for whole cell
10 assays, and from which microsomes were prepared for microsomal assays, were human osteosarcoma 143 cells (which specifically express cyclooxygenase-2) and human U-937 cells (which specifically express cyclooxygenase-1). In these assays, 100% activity is defined as the difference between prostaglandin E₂ synthesis in the absence and
15 presence of arachidonate addition. IC₅₀ values represent the concentration of putative inhibitor required to return PGE₂ synthesis to 50% of that obtained as compared to the uninhibited control. Representative results are shown in Table III.

20 Representative Rat Paw Edema Assay – Protocol

Male Sprague-Dawley rats (150-200 g) were fasted overnight and were given po either vehicle (5% tween 80 or 1% methocel) or a test compound at 9 - 10 am. One hr later, a line was
25 drawn using a permanent marker at the level above the ankle in one hind paw to define the area of the paw to be monitored. The paw volume (V_{0h}) was measured using a plethysmometer (Ugo-Basile, Italy) based on the principle of water displacement. The animals were then injected subplantarily with 50 ul of a 1% carrageenan solution in saline (FMC Corp, Maine) into the paw using an insulin syringe with a 25-gauge
30 needle (i.e. 500 ug carrageenan per paw). Three hr later, the paw volume (V_{3h}) was measured and the increases in paw volume (V_{3h} - V_{0h}) were calculated. The animals were euthanized by CO₂ asphyxiation and the absence or presence of stomach lesions scored. Stomach scores were expressed as the sum of total lesions in mm. Paw edema data were

- 59 -

compared with the vehicle-control group and percent inhibition calculated taking the values in the control group as 100%. Since a maximum of 60 - 70% inhibition (paw edema) was obtained with standard NSAIDs, ED₃₀ values were used for comparison. All treatment groups were coded to eliminate observer bias. With this protocol, the ED₃₀ for Indomethacin is 1.0 mg/kg. Representative results are shown in Table IV.

Table III*

Example	Whole Cells			Microsomes		
	Conc. (nM)	COX-2 % inhib.	COX-1 % inhib.	Conc. (nM)	COX-2 % inhib.	COX-1 % inhib.
1	100	96	12	100	53	8
2	10	69	0	10	49	25
3	10	42		10	33	19
3	100	100		100	76	12
4				10	47	2
5	10	0	0	10	43	31
6	100	78		100	19	16
7	100	74	0	1000	58	16
8	10	41				
8	100	89				
9	100	83		100	37	9
10	100	95		100	71	12
11	100	39		100	46	7
12	100	54				
13	10	41		10	52	7
13	100	84		10	58	10
14	10	73		10	45	29
14	100	89		100	63	0
14	1000	101		1000	69	0

- 60 -

	Example	Conc. (nM)	COX-2 % inhib.	COX-1 % inhib.		Conc. (nM)	COX-2 % inhib.	COX-1 % inhib.
5	15	20	39					
	15	80	76					
	15	160	95					
	16	20	41					
	16	40	50					
10	16	160	85					
	17	40	41					
	17	160	77					
	18	40	24					
	18	160	58					
15	19	40	21					
	19	160	59					
	20	10	70					
	20	40	91					
	21	10	50					
20	21	40	94					
	22	20	39					
	22	160	98					
	23	20	50					
	23	160	88					
25	24	40	43					
	24	160	78					
	25	160	40					
	26	80	27					
	26	160	39					
30	27	20	38					
	27	160	97					

- 61 -

	Example	Conc. (nM)	COX-2 % inhib.	COX-1 % inhib.		Conc. (nM)	COX-2 % inhib.	COX-1 % inhib.
5	28	20	48					
	28	160	69					
	29	20	78					
	29	160	85					
	30	160	30					
10	31	20	49					
	31	160	87					
	32	5	43					
	32	10	73					
	32	40	92					
15	32	80	99					
	33	160	6					
	34	10	30					
	34	40	80					
	34	160	102					
20	35	20	32					
	35	40	57					
	35	160	83					
	36	10	11					
	36	40	50					
25	36	160	89					
	37	10	53					
	37	40	82					
	37	160	93					
	38	10	25					
30	38	40	63					
	38	160	88					
	39	10	17					

- 62 -

	Example	Conc. (nM)	COX-2 % inhib.	COX-1 % inhib.		Conc. (nM)	COX-2 % inhib.	COX-1 % inhib.
5	39	160	84					
	40	10	43					
	40	40	72					
	40	160	96					
	41							
10	41							
	42	20	10					
	42	160	44					
	43	10	78					
	43	40	101					
15	44	20	14					
	44	40	55					
	44	160	106					
	45	10	16					
	45	40	61					
20	45	160	101					
	46	10	76					
	46	40	94					
	46	160	97					
	47	10	61					
25	47	40	74					
	47	160	101					
	48	10	7					
	48	160	47					
	49	10	53					
30	49	40	91					
	49	80	99					
	50	80	42					



- 63 -

Example	Conc. (nM)	COX-2 % inhib.	COX-1 % inhib.		Conc. (nM)	COX-2 % inhib.	COX-1 % inhib.
51	5	49					
51	20	95					
51	40	102					
52	10	50					
52	40	82					
52	160	102					
53	10	54					
53	40	96					
53	160	102					
54	10	81					
54	80	91					
54	160	99					
55	10	48					
55	80	59					
55	160	65					




* In the whole cell assay Ibuprofen has an IC₅₀ for COX-1 of 1000 nM, and an IC₅₀ for COX-2 of 3000 nM. Similarly, Indomethacin has an IC₅₀ for COX-1 of 100 nM, and an IC₅₀ for COX-2 of 10 nM.

- 64 -




Table IV

ED30(mg/kg)	STRUCTURE
~3.00	 <chem>COs(=O)(=O)c1ccc(cc1)-c2cc(sc2-c3ccc(cc3)S(=O)(=O)C)S(=O)(=O)C</chem>
>10.00	 <chem>Fc1ccc(cc1)-c2cc(sc2-c3ccc(cc3)F)S(=O)(=O)C</chem>




- 65 -

5	1.40	
10		
15	2.80 (in 1% methocel) 0.72	
20		
25	0.43	
30		




- 67 -

5	<0.30	
10		
15	0.42	
20		
25	0.034	
30		




- 68 -

5	2.03	 <chem>COS(=O)c1ccc(cc1)C2=C(C(=O)O2)c3cc(F)cc(F)c3</chem>
15	1.49	 <chem>COS(=O)c1ccc(cc1)C2=C(C(=O)O2)c3cc(F)c(F)cc3</chem>
25	0.35	 <chem>COS(=O)c1ccc(cc1)C2=C(C(=O)O2)c3cc(F)c(F)cc3</chem>
30		




- 69 -

5	0.33	 <chem>COS(=O)c1ccc(cc1)C2=C(C(=O)O2)c3ccc(cc3)S(=O)(=O)C</chem>
15	0.90	 <chem>COS(=O)c1ccc(cc1)C2=C(C(=O)O2)c3ccc(cc3)Cl</chem>
25	0.38	 <chem>COS(=O)c1ccc(cc1)C2=C(C(=O)O2)c3ccccc3</chem>
30		




- 70 -

5	0.88	 <chem>COS(=O)c1ccc(cc1)C2=C(C(=O)OC2)c3cc(Cl)cc(Br)c3</chem>
15	0.47	 <chem>COS(=O)c1ccc(cc1)C2=C(C(=O)OC2)c3cc(Cl)cc(F)c3</chem>
25	0.71	 <chem>COS(=O)c1ccc(cc1)C2=C(C(=O)OC2)c3ccc(Cl)cc3</chem>
30		




- 71 -

5	~1.00	
15	1.85	
25	0.22 0.23	
30		




- 72 -

5	0.43	
10		
15	2.17	
20		
25	0.81	
30		




- 73 -

5	0.68	
15	0.16	
25	~1.00	
30		




- 74 -

5	0.33	
15	0.46	
25	0.76	
30		

- 75 -


5	0.48	
15	0.46	
25	0.26	
30		

- 76 -


5	0.55	
10		
15	0.25	
20		
25	ED ₃₀ < 0.30 ED ₅₀ = 1.47	
30		

- 77 -



0.1-.3



~0.10



- 78 -

0.13	
0.07	

The invention will now be illustrated by the following non-limiting examples in which, unless stated otherwise:

- (i) all operations were carried out at room or ambient temperature, that is, at a temperature in the range 18-25°C; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 pascals: 4.5-30 mm Hg) with a bath temperature of up to 60°C; the course of reactions was followed by thin layer chromatography (TLC) and reaction times are given for illustration only; melting points are uncorrected and 'd' indicates decomposition; the melting points given are those obtained for the materials prepared as described; polymorphism

- 79 -

may result in isolation of materials with different melting points in some preparations; the structure and purity of all final products were assured by at least one of the following techniques: TLC, mass spectrometry, nuclear magnetic resonance (NMR) spectrometry or microanalytical data; yields are given for illustration only; when given, NMR data is in the form of delta (δ) values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as internal standard, determined at 300 MHz or 400 MHz using the indicated solvent; conventional abbreviations used for signal shape are: s. singlet; d. doublet; t. triplet; m. multiplet; br. broad; etc.: in addition "Ar" signifies an aromatic signal; chemical symbols have their usual meanings; the following abbreviations have also been used v (volume), w (weight), b.p. (boiling point), m.p. (melting point), L (liter(s)), mL (milliliters), g (gram(s)), mg (milligrams(s)), mol (moles), mmol (millimoles), eq (equivalent(s)).

The following abbreviations have the indicated meanings:

	Ac	=	acetyl
	Bn	=	benzyl
20	DBU	=	1,8-diazabicyclo[5.4.0]undec-7-ene
	DIBAL	=	diisobutylaluminum hydride
	DMAP	=	4-(dimethylamino)pyridine
	DMF	=	N,N-dimethylformamide
	Et ₃ N	=	triethylamine
25	LDA	=	lithium diisopropylamide
	m-CPBA	=	metachloroperbenzoic acid
	MMPP	=	monoperoxyphthalic acid
	MPPM	=	monoperoxyphthalic acid, magnesium salt 6H ₂ O
30	Ms	=	methanesulfonyl = mesyl = SO ₂ Me
	MsO	=	methanesulfonate = mesylate
	NSAID	=	non-steroidal anti-inflammatory drug
	OXONE®	=	2KHSO ₅ •KHSO ₄ •K ₂ SO ₄
	PCC	=	pyridinium chlorochromate

- 80 -

	PDC	=	pyridinium dichromate
	Ph	=	phenyl
	Phe	=	benzenediyl
5	Pye	=	pyridinediyl
	r.t.	=	room temperature
	rac.	=	racemic
	SAM	=	aminosulfonyl or sulfonamide or SO ₂ NH ₂
	TBAF	=	tetra-n-butylammonium fluoride
10	Th	=	2- or 3-thienyl
	TFAA	=	trifluoroacetic acid anhydride
	THF	=	tetrahydrofuran
	Thi	=	thiophenediyl
	TLC	=	thin layer chromatography
15	TMS-CN	=	trimethylsilyl cyanide
	Tz	=	1H (or 2H)-tetrazol-5-yl
	C ₃ H ₅	=	allyl

Alkyl Group Abbreviations

20	Me	=	methyl
	Et	=	ethyl
	n-Pr	=	normal propyl
	i-Pr	=	isopropyl
	n-Bu	=	normal butyl
25	i-Bu	=	isobutyl
	s-Bu	=	secondary butyl
	t-Bu	=	tertiary butyl
	c-Pr	=	cyclopropyl
	c-Bu	=	cyclobutyl
30	c-Pen	=	cyclopentyl
	c-Hex	=	cyclohexyl

EXAMPLE 13-(4-Aminosulfonyl)phenyl)-2-(4-fluorophenyl)-5-(2-hydroxy-2-propyl)thiophene

5

Step 1: 1-(4-Fluorophenyl)-2-(4-(methylthio)phenyl)ethanone

To 4-fluorobenzaldehyde (5.40 g) in 1,2-dichloroethane (43.50 mL) were added TMS-CN (4.32 g) and ZnI₂ (44 mg). After 0.5 h at r.t., the solvent was removed *in vacuo*. To the resulting TMS
10 cyanohydrin (9.20 g) in THF (42.0 mL) at -78°C was added dropwise a solution of LDA 0.51M in THF (88.9 mL). After a period of 0.5 h, a THF solution (30.0 mL) of 4-(chloromethyl)thioanisole (9.93 g) was added dropwise over 0.5 h. After 18 h at +5°C, the resulting mixture was treated with TBAF (57.5 mL) followed by a 25% aqueous solution of
15 NH₄OAc (100 mL) and extracted with EtOAc (2 x 150 mL). After evaporation, a 10:1 mixture of Et₂O and hexane (200 mL) was added to the crude ketone. After stirring for 10 h and filtration, the title product was obtained as a solid by filtration (2.40 g).
1H NMR (CD₃COCD₃): δ 2.45 (3H, s), 4.34 (2H, s), 7.19-7.29 (6H, m),
20 8.14 (2H, q).

Step 2: Cis,trans-3-chloro-3-(4-fluorophenyl)-2-(4-(methylthio)-phenyl)propenal

To a solution of 1-(4-fluorophenyl)-2-(4-(methylthio)phenyl
25 ethanone (2.50 g) in 1,2-dichloroethane (27.0 mL) were introduced the Vilsmeier reagent (Aldrich catalog, 1992-1993) 3.3M (11.6 mL) and DMAP (1.17 g). After a period of 4 h at 80°C, the reaction mixture was extracted with EtOAc and 25% aqueous solution of NH₄OAc. After evaporation *in vacuo* and drying for a few hours, the title product was
30 used as such for the next step.
1H NMR (CD₃COCD₃): δ 2.40 and 2.48 (3H, 2s), 6.90-7.80 (8H, m), 9.55 (1H, s).

- 82 -

Step 3: 5-(4-Fluorophenyl)-4-(4-(methylthio)phenyl)thiophene-2-carboxylic acid methyl ester

To a solution of cis,trans 3-chloro-3-(4-fluorophenyl)-2-(4-(methylthio)phenyl)propenal (3.00 g) in pyridine (12.0 mL) were added
5 methyl thioglycolate (1.16 mL) and Et₃N (4.09 mL). The resulting mixture was then heated at 80°C for 2 h. After extraction with EtOAc and washing with 3N HCl, the title product was purified by flash chromatography (30% EtOAc in hexane) (2.00 g).
1H NMR (CD₃COCD₃): δ 2.48 (3H, s), 3.88 (3H, s), 7.11 (2H, t), 7.21
10 (4H, s), 7.37 (2H, q), 7.80 (1H, s).

Step 4: 5-(4-Fluorophenyl)-4-(4-(methylsulfinyl)phenyl)thiophene-2-carboxylic acid methyl ester

To a solution of 5-(4-fluorophenyl)-4-(4-(methylthio)-
15 phenyl)thiophene-2-carboxylic acid methyl ester (5.60 g) in CH₂Cl₂ (84.0 mL) at 0°C was added portionwise m-CPBA 50 to 60% (5.39 g). After TLC showed completion (50% EtOAc in hexane), the reaction mixture was extracted with saturated NaHCO₃, dried over Na₂SO₄,
20 filtered and evaporated to dryness to provide the title compound as a white foam (5.00 g).
1H NMR (CD₃COCD₃): δ 2.75 (3H, s), 3.92 (3H, s), 7.15 (2H, t), 7.40 (2H, q), 7.52 (2H, d), 7.66 (2H, d), 7.90 (1H, s).

Step 5: 4-(4-(Aminosulfonyl)phenyl)-5-(4-fluorophenyl)thiophene-2-carboxylic acid methyl ester

5-(4-Fluorophenyl)-4-(4-(methylsulfinyl)phenyl)thiophene-
2-carboxylic acid methyl ester (0.500 g) was dissolved in TFAA (10.0 mL) and refluxed for 0.5 h. The solvent was then removed *in vacuo* and the resulting residue was co-evaporated 10 times with a Et₃N-MeOH
30 solution (1:1) (100.0 mL) to provide a viscous oil after pumping for a few hours. The oil was dissolved in HOAc (10.0 mL) and treated at +10°C with Cl₂ in HOAc (1.9M) (3.5 mL). After 20 min, the solvent was removed under reduced pressure and after pumping, THF (20.0 mL) was added to the resulting mass of product. After bubbling NH₃ through for a

- 83 -

few minutes at 0°C, the reaction mixture was stirred for 0.5 h at r.t. After extraction with EtOAc - 25% NH₄OAc solution and flash chromatography (30 to 40% EtOAc in hexane), the title product was obtained as a white solid (0.210 g).

5 ¹H NMR (CD₃COCD₃): δ 3.90 (3H, s), 6.55 (2H, bs), 7.13 (2H, t), 7.40 (2H, q), 7.46 (2H, d), 7.83 (2H, d), 7.90 (1H, s).

Step 6: 3-(4-Aminosulfonyl)phenyl)-2-(4-fluorophenyl)-5-(2-hydroxy-2-propyl)thiophene

10 To 4-(4-aminosulfonyl)phenyl)-5-(4-fluorophenyl)-thiophene-2-carboxylic acid methyl ester (0.460 g) in THF (5.70 mL) at 0°C was added MeMgBr (1.4M) in toluene-THF solution (5.00 mL). The mixture was then stirred at r.t. for a few hours. The reaction was quenched by the addition of 25% NH₄OAc solution, extracted with
15 EtOAc and dried over with Na₂SO₄. The title compound was purified by flash chromatography (40 to 50% EtOAc in hexane) (0.300 g).
¹H NMR (CD₃COCD₃): δ 1.65 (6H, s), 4.52 (1H, s), 6.55 (2H, bs), 7.09 (3H, m), 7.34 (2H, dd), 7.30 (2H, m), 7.43 (2H, d), 7.82 (2H, d).

20 Analysis calcd. for C₁₉H₁₈FNO₃S₂
 C, 58.31; H, 4.60; N, 3.58
 Found: C, 57.94; H, 4.66; N, 3.44

EXAMPLE 2

25

3-(4-(Aminosulfonyl)phenyl)-2-(4-fluorophenyl)thiophene

Step 1: 4-(4-(Aminosulfonyl)phenyl)-5-(4-fluorophenyl)thiophene-2-carboxylic acid

30

To a solution of 4-(4-(aminosulfonyl)phenyl)-5-(4-fluorophenyl)thiophene-2-carboxylic acid methyl ester (Example 1, Step 5) (0.210 g) in THF (2.0 mL) were added MeOH (1.0 mL), NaOH 1N (1.0 mL) and a few drops of NaOH 10N. The resulting mixture was heated at

- 84 -

45°C for 2 h and the reaction was then partitioned between EtOAc and HCl (3N) to provide the title product as a white solid (0.200 g).

¹H NMR (CD₃COCD₃) δ 6.60 (2H, s), 7.15 (2H, t), 7.35 (2H, q), 7.45 (2H, d), 7.82 (2H, d), 7.87 (1H, s).

5

Step 2: 3-(4-(Aminosulfonyl)phenyl)-2-(4-fluorophenyl)thiophene

To a solution of 3-(4-(aminosulfonyl)phenyl)-2-(4-fluorophenyl)thiophene-2-carboxylic acid (0.280 g) in quinoline (4.0 mL) was added Cu bronze (0.300 g). After 0.5 h at 180°C under nitrogen, the reaction mixture was extracted with EtOAc and HCl 3N, dried over Na₂SO₄ and purified by flash chromatography (30% EtOAc in hexane) to give the title compound as a white solid (0.180 g).

10

¹H NMR (CD₃COCD₃): δ 6.60 (2H, bs), 7.15 (2H, t), 7.29 (1H, d), 7.35 (2H, q), 7.45 (2H, d), 7.60 (1H, d), 7.83 (2H, d).

15

Analysis calcd for C₁₆H₁₂FNO₂S₂

C, 57.65; H, 3.60; N, 4.20

Found: C, 57.62; H, 3.59; N, 4.15

20

EXAMPLE 3

3-(4-(Aminosulfonyl)phenyl)-2-(4-fluorophenyl)-5-(2-propyl)thiophene

¹H NMR (CD₃COCD₃) δ 1.40 (6H, d), 3.25 (1H, septuplet), 6.58 (2H, bs), 7.05 (1H, s), 7.15 (2H, t), 7.32 (2H, dd), 7.46 (2H, d), 7.80 (2H, d).

25

Analysis calcd. for C₁₉H₁₈FNO₂S₂

C, 60.80; H, 4.80; N, 3.73

Found: C, 60.59; H, 4.45; N, 3.60

30

- 85 -

EXAMPLE 43-(4-(Aminosulfonyl)phenyl)-2-cyclohexylthiophene

5 ^1H NMR ($\text{CD}_3)_2\text{CO}$) δ 1.24-1.40 (3H, m), 1.40-1.56 (2H, m), 1.65-1.85 (3H, m), 1.90-2.0 (2H, m), 3.18 (1H, m), 6.58 (2H, bs), 7.05 (1H, d), 7.37 (1H, d), 7.58 (2H, d), 7.97 (2H, d).

EXAMPLE 5

10

5-(4-Carboxyphenyl)-4-(4-(methylsulfonyl)phenyl)thiophene-2-carboxylic acid

15 Step 1: 4-(2-(4-(Methylthio)phenyl)-1-oxo-ethyl)benzoic acid methyl ester

To methyl 4-formylbenzoate (10.30 g) in 1,2-dichloroethane at r.t. were added TMS-CN (6.58 mL) and ZnI_2 (2.00 g), after 0.5 h at r.t., the solvent was removed *in vacuo*. To the resulting TMS cyanohydrin (5.00 g) in THF (22.0 mL) at -78°C was added dropwise a solution of
20 LDA 0.87 M in THF (26.2 mL). After a period of 0.5 h, a THF solution (10.0 mL) of 4-(chloromethyl)thioanisole was added dropwise over 0.5 h. The temperature was then brought slowly to -20°C then to 5°C for 2 h and TBAF 1M in THF (50.0 mL) was added. After the addition of 25%
25 aqueous solution of NH_4OAc , the reaction mixture was extracted with EtOAc, dried over NaSO_4 , evaporated *in vacuo* and purified by flash chromatography (20 to 30% EtOAc in hexane) to afford the title compound as a white solid (7.00 g).

30 Step 2: 4-(1-Oxo-2-(4-(methylsulfonyl)phenyl)ethyl) benzoic acid methyl ester

To 7.10 g of 4-(2-(4-(methylthio)phenyl)-1-oxo-ethyl) benzoic acid methyl ester in MeOH (100 mL) was added oxone (21.0 g) in H_2O (20.0 mL) at 0°C . After a few hours at r.t., the reaction mixture

- 86 -

was extracted with EtOAc and H₂O to afford after flash chromatography (50 to 100% EtOAc in hexane), the title product as a white solid (3.20 g).
1H NMR (CD₃COCD₃) δ 3.10 (3H, s), 3.95 (3H, s), 4.65 (2H, s), 7.60 (2H, d), 7.96 (2H, d), 8.20 (4H, q).

Step 3: Cis,trans 4-(1-Chloro-3-oxo-2-(4-(methylsulfonyl)phenyl)-1-propenyl)benzoic acid methyl ester

To a solution of 4-(1-oxo-2-((4-methylsulfonyl)phenyl)-ethyl) benzoic acid (1.70 g) in 1,2-dichloroethane (15.0 mL) were added the Vilsmeier reagent 3.3 M (6.2 mL) and DMAP (0.624 g). The resulting mixture was heated at 80°C for 4 h. The reaction mixture was then extracted with 25% aqueous solution of NH₄OAc and EtOAc. After drying over Na₂SO₄ and evaporation the title compound was obtained as an oil and used as such for the next step.

Step 4: 5-(4-(Methoxycarbonyl)phenyl)-4-(4-(methylsulfonyl)-phenyl)thiophene-2-carboxylic acid methyl ester

Prepared from 4-(1-chloro-3-oxo-2-(4-methylsulfonyl)-phenyl)-1-propenyl)benzoic acid methyl ester as for Example 1, Step 3.
1H NMR (CD₃COCD₃) δ 3.13 (3H, s), 3.85 and 3.92 (6H, 2s), 7.50 (2H, d), 7.55 (2H, d), 7.90 (2H, d), 7.92 (1H, s), 7.92 (2H, d).

Step 5: 5-(4-(Carboxyphenyl)-4-(4-(methylsulfonyl)phenyl)-thiophene-2-carboxylic acid

Prepared from 5-(4-(methoxycarbonyl)phenyl)-4-(4-(methylsulfonyl)phenyl) thiophene-2-carboxylic acid methyl ester as for Example 2, Step 1.

1H NMR (CD₃COCD₃) δ 3.15 (3H, s), 7.50 (2H, d), 7.62 (2H, d), 7.95 (2H, d), 7.98 (1H, s), 8.05 (2H, d).

Analysis calcd. for C₁₉H₁₄O₆S₂•0.1 H₂O

C, 56.46; H, 3.51

Found: C, 56.18; H, 3.51

EXAMPLE 6

4-(4-Fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)phenyl)thiazole

5 Step 1: 1-(4-Fluorophenyl)-2-(4-(methylsulfonyl)phenyl)ethanone
To 1-(4-Fluorophenyl)-2-(4-(methylthio)phenyl)ethanone of
Example 1, Step 1 (17.9 g) in a solution of CH₂Cl₂-MeOH (272.0
mL/27.0 mL) at 0°C was added MPPM (28.0 g). The cooling bath was
then removed and the reaction mixture stirred at r.t. for 1 h. At 0°C,
10 additional MPPM (28.0 g) was added and the reaction mixture kept for
1.5 h at r.t. The insoluble material was filtered followed by evaporation
of the solvents, the residue was then extracted with CH₂Cl₂-NaHCO₃.
After evaporation *in vacuo*, the resulting solid was washed with ether-
hexane (1:1) and filtered to provide the title compound 16.8 g.
15 ¹H NMR (CD₃COCD₃) δ 3.13 (3H, s), 3.58 (2H, s), 7.29 (2H, t), 7.55
(2H, d), 7.88 (2H, d), 8.20 (2H, dd).

Step 2: **2-Bromo-1-(4-fluorophenyl)-2-(4-(methylsulfonyl)phenyl)-ethanone**

20 To 1-(4-Fluorophenyl)-2-(4-(methylsulfonyl)phenyl)-ethanone (1.00 g) in CH₂Cl₂ containing CHCl₃ (1.0 mL) and CCl₄ (1.0 mL) was added bromine (0.614 g). After shining light for 1 h, the reaction was quenched with Na₂S₂O₄, extracted with CH₂Cl₂, dried over Na₂SO₄ and evaporated to yield the title compound which was used

25 as such for the next step (1.10 g).
1H NMR (CD₃COCD₃) δ 3.10 (3H, s), 7.05 (1H, s), 7.30 (2H, t), 7.87 (2H, d), 7.95 (2H, d), 8.25 (2H, dd).

Step 3: 4-(4-Fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)phenyl)-thiazole

To 2-bromo-1-(4-fluorophenyl)-2-(4-(methylsulfonyl)-phenyl)-ethanone (1.10 g) in ethanol (15.0 mL) were added thioacetamide (0.266 g) and pyridine (0.300 mL). After refluxing for 2 h, the reaction mixture was extracted with EtOAc, 25% NH₄OAc and

- 88 -

purified by flash chromatography (50% EtOAc in hexane then 90% Et₂O in hexane) to yield the title compound (0.320 g).

¹H NMR (CD₃COCD₃) δ 2.72 (3H, s), 3.15 (3H, s), 7.09 (2H, t), 7.52 (2H, dd), 7.60 (2H, d), 7.92 (2H, d).

5

Analysis calcd. for C₁₇H₁₄FNO₂S₂

C, 58.78; H, 4.03; N, 4.03

Found: C, 58.71, H, 4.17; N, 3.85

10

EXAMPLE 7

2-(4-Fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-2-cyclopenten-1-one

15

Step 1: 1-(4-Fluorophenyl)-5-hexen-2-one

To a suspension of 14.6 g (80 mmol) of CdCl₂ in 200 mL of ether cooled to 0°C was added 115 mL of 1.3M solution of 3-butene-1-magnesium bromide dropwise. The mixture was refluxed for 1 h and ether was then removed by distillation. Benzene (500 mL) was introduced, followed by a solution of 17.5 g (100 mmol) 4-fluorophenyl-acetyl chloride. After refluxing for 1 h, the reaction mixture was quenched with 200 mL of saturated aqueous NH₄Cl, 50 mL of 1N HCl, and extracted with 200 mL of 1:1 hexane/EtOAc. The organic phase was dried over MgSO₄ and concentrated. The residue was purified by flash chromatography eluted with 4:1 hexane/EtOAc to give 15 g of the title product.

20

25

¹H NMR (CDCl₃) δ 2.40 (2H, t), 2.53 (2H, t), 3.63 (2H, s), 4.90-4.98 (2H, m), 5.67-5.78 (1H, m), 6.98 (2H, t), 7.13 (2H, m).

30

Step 2: 1-(4-Fluorophenyl)-5-oxo-2-pentanone

A solution of 14 g of 1-(4-fluorophenyl)-5-hexen-2-one in 200 mL of 3:1 CH₂Cl₂/MeOH was cooled to -78°C and treated with excess ozone. The resulting mixture was treated with 15 g of triphenylphosphine and stirred at room temperature for 1 h. The reaction

- 89 -

mixture was concentrated and flash chromatographed with 3:1 hexane/EtOAc to give 8 g of the title ketoaldehyde.

¹H NMR (CDCl₃) δ 2.72 (4H, s), 3.71 (2H, s), 6.99 (2H, t), 7.14 (2H, m), 9.73 (1H, s).

5

Step 3: 2-(4-Fluorophenyl)-2-cyclopenten-1-one

A solution of 8 g of 1-(4-fluorophenyl)-5-oxo-2-pentanone in 300 mL of MeOH was treated with 2 g of NaOMe. The mixture was stirred for 2 h and then quenched with 5 mL of HOAc. The solvent was

10

evaporated and the residue purified by flash chromatography, eluting with 3:1 hexane/EtOAc to give 7 g of the title product.
¹H NMR (CDCl₃) δ 2.57 (2H, m), 2.68 (2H, m), 7.04 (2H, J=8.8 Hz, t), 7.67 (2H, J=8.8, 5.5 Hz, dd), 7.77 (1H, m).

15

Step 4: 1-(4-(Methylthio)phenyl)-2-(4-fluorophenyl)-2-cyclopenten-1-ol

To a solution of 3.86 g (19 mmol) of 4-bromothioanisole in 90 mL of Et₂O cooled at -78°C, was added 22 mL of 1.7M solution of t-BuLi in pentane (38 mmol) dropwise. The reaction mixture was stirred

20

for 15 min at -78°C and a solution of 2.23 g of 2-(4-Fluorophenyl)-2-cyclopenten-1-one in 10 mL of Et₂O was added. After stirring for 15 min at -78°C, the reaction mixture was warmed to 0°C, and quenched with 50 mL of sat. NH₄Cl. The product was extracted with 100 mL EtOAc, dried over Na₂SO₄, and purified by flash chromatography, eluted

25

Step 5: 2-(4-Fluorophenyl)-3-(4-(methylthio)phenyl)-2-cyclopenten-1-one

To a suspension of PCC (4.5 g, 20.9 mmol) and 10 g of anhydrous 4Å molecular sieves in 150 mL of CH₂Cl₂ was added a solution of 2.2 g (7.3 mmol) of 1-(4-(methylthio)phenyl)-2-(4-

30

- 90 -

fluorophenyl)-2-cyclopenten-1-ol in 20 mL CH₂Cl₂. The mixture was stirred for 1 h at r.t. and then diluted with 300 mL of Et₂O. After filtration and concentration, the residue was flash chromatographed with 2:1 hexane/EtOAc to give 1.5 g of the title product.

5 ¹H NMR (CDCl₃) δ 2.45 (3H, s), 2.68 (2H, m), 3.00 (2H, m), 7.02 (2H, J=8.6 Hz, t), 7.11 (2H, J=8.6 Hz, d), 7.15-7.23 (4H, m).

Step 6: 2-(4-Fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-2-cyclopenten-1-one

10 To a solution of 50 mg (0.17 mmol) of 2-(4-Fluorophenyl)-3-(4-methylthio)phenyl)-2-cyclopenten-1-one in 8 mL of 10:1 CH₂Cl₂/MeOH was added 124 mg (0.2 mmol) of MPPM. The reaction mixture was stirred at room temperature for 2 h and then diluted with 10 mL of 1:1 hexane/EtOAc. After filtration and concentration, the residue was purified by flash chromatography eluted with 2:1 EtOAc/hexane to give 45 mg of the title product.

15 ¹H NMR (acetone-d₆) δ 2.67 (2H, m), 3.14 (3H, s), 3.16 (2H, m), 7.05-7.10 (2H, m), 7.20-7.25 (2H, m), 7.63 (2H, d), 7.93 (2H, d).

20

EXAMPLE 8

4-(4-(Methylsulfonyl)phenyl)-5-(4-fluorophenyl)-isothiazole

25 To a solution of 338 mg (1 mmol) of cis,trans 3-chloro-3-(4-fluorophenyl)-2-(4-(methylsulfonyl)phenyl)propenal in 5 mL of acetone was added 230 mg (3 mmol) of NH₄SCN. The reaction mixture was refluxed for 3 h, and then quenched with 20 mL of saturated NaHCO₃. The product was extracted with 100 mL of EtOAc, dried over Na₂SO₄, concentrated and purified by flash chromatography eluted with 3:2 hexane/EtOAc to give 250 mg of the title product.

30 ¹H NMR (CDCl₃) δ 8.57 (1H, s), 7.93 (3H, d), 7.50 (2H, d), 7.30 (2H, t), 7.08 (2H, t).

EXAMPLE 93-(4-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone5 Step 1: 2-Bromo-1-(4-(methylsulfonyl)phenyl)ethanone

A solution of 197 g of 4-(Methylthio)acetophenone (ref: JACS, 1952, 74, p. 5475) in 700 mL of MeOH and 3500 mL of CH₂Cl₂ was added 881 g of MMPP over a period of 30 min. After 3 h at room temperature the reaction mixture was filtered and the filtrate was washed
10 with 2L of saturated aqueous solution of NaHCO₃ and 1L of brine. The aqueous phase was further extracted with 2L of CH₂Cl₂. The combined extracts was dried over Na₂SO₄ concentrated to give 240 g of 4-(methylsulfonyl)acetophenone as a white solid.

To a cooled (-5°C) solution of 174 g of 4-(methylsulfonyl)-
15 acetophenone in 2.5L of CHCl₃ was added 20 mg of AlCl₃, followed by a solution of 40 mL of Br₂ in 300 mL CHCl₃. The reaction mixture was then treated with 1.5L of water and the CHCl₃ was separated. The aqueous layer was extracted with 1L of EtOAc. The combined extracts was dried over Na₂SO₄ and concentrated. The crude product was
20 recrystallized from 50/50 EtOAc/hexane to give 210 g of 2-bromo-1-(4-(methylsulfonyl)phenyl)ethanone as a white solid.

Step 2:

To the product of Step 1 (216 mg) dissolved in acetonitrile
25 (4 mL) was added Et₃N (0.26 mL), followed by 4-fluorophenylacetic acid (102 mg). After 1.5 h at room temperature 0.23 mL of DBU was added. The reaction mixture was stirred for another 45 min and then treated with 5 mL of 1N HCl. The product was extracted with EtOAc, dried over Na₂SO₄ and concentrated. The residue was purified by flash
30 chromatography (40% EtOAc in hexane) to yield 150 mg of the title compound as a solid.
1H NMR (CD₃COCD₃) δ 3.15 (3H, s), 5.36 (3H, s), 7.18 (2H, J=8.9 Hz, t), 7.46 (2H, m), 7.7 (2H, J=8.65 Hz, d), 7.97 (2H, J=8.68, d).

- 92 -

EXAMPLE 103-(4-Fluorophenyl)-4-(4-(aminosulfonyl)phenyl)-2-(2H)-furanone

5 ¹H NMR (CD₃COCD₃) δ 5.34 (2H, s), 6.67 (2H, bd), 7.18 (2H, m), 7.46 (2H, m), 7.61 (2H, m), 7.90 (2H, m).
M.P. 187-188°C (d).

EXAMPLE 11

10

3-(4-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)furanStep 1:

15 Using the product of Example 10, (0.2 g) in THF (5 mL) and toluene (3 mL) was added slowly at -78°C a solution of DIBAL (0.72 mL, 1M in toluene). After 15 min, the solution was warmed up to 0°C for another 15 min. This mixture was then poured into a chilled aqueous solution of sodium potassium tartrate and EtOAc. The organic layer was stirred for 0.5 h with a few crystals of camphor sulfonic acid. This
20 solution was then concentrated and purified by flash chromatography to yield the title compound.

¹H NMR (CDCl₃) δ 3.1 (3H, s), 7.02 (2H, J=8.9, t), 7.18 (2H, m), 7.4 (2H, J=8.8 Hz, d), 7.58 (1H, s), 7.68 (1H, s), 7.85 (2H, J=8.8 Hz, d).

25

EXAMPLE 125,5-Dimethyl-3-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

30

Step 1: Methyl 2-trimethylsilyloxyisobutyrate

To a solution of 1.2 mL (10.4 mmol) of methyl 2-hydroxyisobutyrate in 50 mL of CH₂Cl₂ were added 1.2 g (17.6 mmol) of imidazole and 2.1 mL (16.6 mmol) of TMSCl. The mixture was stirred at r.t. for 1.5 h and quenched with 20 mL of H₂O. The organic layer was

- 93 -

dried over MgSO_4 , concentrated and passed through a short plug of silica gel eluted with 9:1 hexane/EtOAc. Evaporation of solvent afforded 1.27 g of the title compound as a colorless oil.

^1H NMR (CD_3COCD_3) δ 0.08 (9H, s), 1.38 (6H, s), 3.67 (3H, s).

5

Step 2: 2-Trimethylsilyloxy-4'-(methylthio)isobutyrophenone

A solution of 204 mg (1.0 mmol) of 4-bromothioanisole in 2.5 mL of THF was cooled to -78°C and treated with 0.42 mL of 2.5M n-BuLi solution in hexane. After stirring at -78°C for 1 h, a solution of 380 mg (2.0 mmol) of methyl 2-trimethylsilyloxyisobutyrate in 2 mL of THF was added. The mixture was stirred at -78°C for 2 h and then quenched with NH_4OAc buffer. The product was extracted with EtOAc, dried over MgSO_4 and concentrated. The residue was purified by flash chromatography, eluting with 19:1 hexane/EtOAc to give 95 mg of the title product.

10

15

^1H NMR (CD_3COCD_3) δ 0.05 (9H, s), 1.52 (6H, s), 2.53 (3H, s), 7.33 (2H, d), 8.12 (2H, d).

Step 3: 2-Hydroxy-4'-(methylthio)isobutyrophenone

20

To a solution of 40 mg (0.14 mmol) of 2-trimethylsilyloxy-4'-(methylthio)isobutyrophenone in 2 mL THF was added 0.2 mL of 1M n-Bu₄NF in THF. The resulting mixture was stirred for 30 min and then quenched with 10 mL of NH_4OAc buffer. The product was extracted with EtOAc, dried over MgSO_4 and concentrated. The residue was purified by flash chromatography, eluting with 4:1 hexane/EtOAc to give 25 mg of the title product.

25

^1H NMR (CD_3COCD_3) δ 1.50 (6H, s), 2.54 (3H, s), 4.68 (1H, s), 7.30 (2H, d), 8.15 (2H, d).

Step 4: 2-(4-Fluorophenylacetoxy)-4'-(methylthio)isobutyrophenone

30

To a solution of 72 mg (0.34 mmol) 2-hydroxy-4'-(methylthio)isobutyrophenone in 1.7 mL of CH_2Cl_2 were added 0.2 mL of pyridine and 140 mg (0.81 mmol) of 4-fluorophenylacetyl chloride. The mixture was stirred at room temperature overnight and then

- 94 -

quenched with NH₄OAc buffer. The product was extracted with EtOAc, dried over MgSO₄ and concentrated. The crude product was purified by flash chromatography eluting with 8:1 hexane/EtOAc to give 95 mg of the title product.

5 ¹H NMR (CD₃COCD₃) δ 1.62 (3H, s), 1.67 (3H, s), 2.48 (3H, s), 3.79 (2H, s), 7.0-7.3 (6H, m), 7.78 (2H, d).

Step 5: 5,5-Dimethyl-3-(4-fluorophenyl)-4-(4-(methylthio)phenyl)-2-(5H)-furanone

10 To a solution of 95 mg of 2-(4-fluorophenylacetoxyl)-4'-(methylthio)-isobutyrophenone in 4 mL of CH₂Cl₂ was added 0.2 mL of 1,8-diazabicyclo(5.4.0)undec-7-ene. The mixture was stirred for 4 h and diluted with NH₄OAc buffer. The product was extracted with EtOAc, dried over MgSO₄ and concentrated. The residue was purified by flash
15 chromatography, eluting with 20:1 toluene/EtOAc to give 75 mg of the title product.

¹H NMR (CD₃COCD₃) δ 1.58 (6H, s), 2.50 (3H, s), 7.03 (2H, dd), 7.25-7.35 (4H, m), 7.41 (2H, dd).

20 **Step 6:** 5,5-Dimethyl-3-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

To a solution of 81 mg of 5,5-dimethyl-3-(4-fluorophenyl)-4-(4-(methylthio)phenyl)-2-oxo-2H-dihydrofuran in 1.8 mL of CH₂Cl₂ and 0.2 mL of MeOH was added 250 mg of MPPM. The reaction mixture was stirred at
25 room temperature for 1 h and then quenched with aqueous NaHCO₃.

The product was extracted with EtOAc, dried over MgSO₄ and concentrated. The crude product was purified by flash chromatography eluting with 1:1 hexane/EtOAc to give 73 mg of the title product.

30 ¹H NMR (CD₃COCD₃) δ 1.62 (6H, s), 3.15 (3H, s), 7.02 (2H, dd), 7.40 (2H, dd), 7.65 (2H, d), 8.03 (2H, d).

5,5-Dimethyl-3-(3-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone was prepared in an analogous manner (m.p. 172.7°C).

Analysis: Calculated: C, 63.32; H, 4.75;

Found: C, 63.50; H, 4.79;

- 95 -

EXAMPLE 132-((4-aminosulfonyl)phenyl)-3-(4-fluorophenyl)thiophene

5 ^1H NMR (CD_3COCD_3) δ 6.60 (2H, bs), 7.12 (2H, t), 7.25 (1H, d), 7.35 (2H, m), 7.45 (2H, d), 7.65 (1H, d), 7.85 (2H, d).

Analysis calculated for $\text{C}_{16}\text{H}_{12}\text{FNS}_2\text{O}_2$

C, 57.65; H, 3.60; N, 4.20

10 Found: C, 57.55; H, 3.79; N, 4.03

EXAMPLE 14

15 3-(4-(Trifluoroacetylaminosulfonyl)phenyl)-2-(4-fluorophenyl)thiophene

^1H NMR (300 MHz, CD_3COCD_3) δ 7.15 (2H, t), 7.30 (3H, m), 7.45 (2H, d), 7.65 (1H, d), 7.95 (2H, d).

EXAMPLE 15

20

3-(2,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

Analysis calculated for $\text{C}_{17}\text{H}_{12}\text{F}_2\text{O}_4\text{S}$

C, 58.28; H, 3.45; S, 9.15

25 Found: C, 58.27; H, 3.50; S, 9.27

EXAMPLE 16

30 3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

To a solution of 3,4-difluorophenylacetic acid (ALDRICH CHIMICAL) (10 g) and 2-bromo-1-(4-(methylsulfonyl)phenyl)ethanone (Example 9, Step 1) (17.3 g) in acetonitrile (200 mL) at room temperature was added slowly triethylamine (20.2 mL). After 1 h at room temperature, the mixture was cooled in an ice bath and treated with 17.4

- 96 -

mL of DBU. After 2 h at 0°C, the mixture was treated with 200 mL of 1N HCl and the product was extracted with EtOAc, dried over Na₂SO₄ and concentrated. The residue was applied on top of a silica gel plug (sintered glass funnel) eluted with 75% EtOAc/hexane, giving after
5 evaporation of the solvent and swish in ethyl acetate, 10 g of the title compound.

Analysis calculated for C₁₇H₁₂F₂O₄S
 C, 58.28; H, 3.45; S, 9.15
10 Found: C, 58.02; H, 3.51; S, 9.35

EXAMPLE 17

15 3-(2,6-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

Analysis calculated for C₁₇H₁₂F₂O₄S
 C, 58.28; H, 3.45; S, 9.15
Found: C, 58.18; H, 3.50; S, 9.44

20

EXAMPLE 18

3-(2,5-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

25 Analysis calculated for C₁₇H₁₂F₂O₄S
 C, 58.28; H, 3.45; S, 9.15
Found: C, 58.89; H, 3.51; S, 9.11

30

- 97 -

EXAMPLE 193-(3,5-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

5 Analysis calculated for C₁₇H₁₂F₂O₄S
 C, 58.28; H, 3.45; S, 9.15
 Found: C, 58.27; H, 3.62; S, 9.32

EXAMPLE 20

10

3-(4-Bromophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

 Analysis calculated for C₁₇H₁₃BrO₄S
 C, 51.94; H, 3.33; S, 8.16
15 Found: C, 51.76; H, 3.42; S, 8.21

EXAMPLE 21

20

3-(4-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

1H NMR (300 MHz, CDCl₃) δ 7.93 (2H, d), 7.49 (2H, d), 7.35 (4H, m),
5.16 (2H, s), 3.06 (3H, s).

EXAMPLE 22

25

3-(4-Methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

 Analysis calculated for C₁₈H₁₆O₅S
 C, 62.78; H, 4.68; S, 9.31
30 Found: C, 62.75; H, 4.72; S, 9.39

EXAMPLE 233-(Phenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

5 To a solution of phenylacetic acid (27.4 g, 201 mmol) and 2-bromo-1-(4-(methylsulfonyl)phenyl)ethanone (Example 9, Step 1) (60 g, 216 mmol, 1.075 eq.) in acetonitrile (630 mL) at 25°C was added slowly triethylamine (30.8 mL, 1.1 eq.). The mixture was stirred for 20 min at room temperature and then cooled in an ice bath. DBU (60.1 mL, 3 eq.) was slowly added. After stirring for 20 min in the ice bath, the reaction
10 was complete and the mixture was acidified with 1N HCl (color changes from dark brown to yellow). Then 2.4 L of ice and water were added, stirred for a few minutes, then the precipitate was filtered and rinsed with water (giving 64 g of crude wet product). The solid was dissolved in 750 mL of dichloromethane (dried over MgSO₄, filtered) and 300 g of silica
15 gel was added. The solvent was evaporated to near dryness (silica gel a bit sticky) and the residue was applied on top of a silica gel plug (sintered glass funnel) eluted with 10% EtOAc/CH₂Cl₂, giving after evaporation of the solvent and swish in ethyl acetate, 36.6 g (58%) of the title compound.

20

Analysis calculated for C₁₇H₁₄O₄S
 C, 64.95; H, 4.49; S, 10.20
Found: C, 64.63; H, 4.65; S, 10.44

25

EXAMPLE 243-(2-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

30 Analysis calculated for C₁₇H₁₃ClO₄S
 C, 58.54; H, 3.76; S, 9.19
Found: C, 58.59; H, 3.80; S, 9.37

- 99 -

EXAMPLE 25

3-(2-Bromo-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-
furanone

Analysis calculated for C₁₇H₁₂BrFO₄S
 C, 49.75; H, 2.93
Found: C, 49.75; H, 3.01

EXAMPLE 26

3-(2-Bromo-4-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-
furanone

¹H NMR (300 MHz, acetone-d₆) δ 7.95 (2H, d), 7.85 (1H, d), 7.63 (2H, dd), 7.55 (1H, dd), 7.45 (1H, d), 5.50 (2H, s), 3.15 (3H, s).

EXAMPLE 27

3-(4-Chloro-2-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-
furanone

¹H NMR (300 MHz, acetone-d₆) δ 8.0 (2H, d), 7.70 (2H, d), 7.50-7.30 (3H, m), 5.35 (2H, s), 3.15 (3H, s).

EXAMPLE 28

3-(3-Bromo-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-
furanone

Analysis calculated for C₁₇H₁₂BrFO₄S
 C, 49.75; H, 2.93
Found: C, 49.44; H, 2.98

- 100 -

EXAMPLE 293-(3-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

5 Analysis calculated for C₁₇H₁₃ClO₄S
 C, 58.54; H, 3.76
 Found: C, 58.29; H, 3.76

EXAMPLE 30

10

3-(2-Chloro-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

 Analysis calculated for C₁₇H₁₂ClFO₄S
15 C, 55.67; H, 3.30
 Found: C, 55.67; H, 3.26

EXAMPLE 31

20 3-(2,4-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

 Analysis calculated for C₁₇H₁₂Cl₂O₄S
 C, 53.28; H, 3.16; S, 8.37
 Found: C, 52.89; H, 3.23; S, 8.58
25

EXAMPLE 323-(3,4-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

30 Analysis calculated for C₁₇H₁₂Cl₂O₄S
 C, 53.28; H, 3.16; S, 8.37
 Found: C, 53.07; H, 3.32; S, 8.51

- 101 -

EXAMPLE 333-(2,6-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

5 Analysis calculated for C₁₇H₁₂Cl₂O₄S
 C, 53.28; H, 3.16; S, 8.37
 Found: C, 52.99; H, 3.22; S, 8.54

EXAMPLE 34

10

3-(3-Chloro-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

¹H NMR (300 MHz, acetone-d₆) δ 8.0 (2H, d), 7.70 (2H, d), 7.60 (1H,
15 d), 7.25-7.40 (2H, m), 5.35 (2H, s), 3.15 (3H, s).

EXAMPLE 35

20

3-(4-Trifluoromethylphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

¹H NMR (CD₃COCD₃) δ 8.10 (2H, d), 7.82-7.93 (4H, m), 7.75 (2H, d),
 5.55 (2H, s), 3.30 (3H, s).

25

EXAMPLE 363-(3-Fluoro-4-methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

30 Analysis calculated for C₁₈H₁₅FO₅S
 C, 59.66; H, 4.17
 Found: C, 59.92; H, 4.37

- 102 -

EXAMPLE 37

3-(3-Chloro-4-methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-
furanone

5

Analysis calculated for C₁₈H₁₅ClO₅S
 C, 57.07; H, 3.99
Found: C, 57.29; H, 4.15

10

EXAMPLE 38

3-(3-Bromo-4-methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-
furanone

15

Analysis calculated for C₁₈H₁₅BrO₅S
 C, 51.08; H, 3.57
Found: C, 51.38; H, 3.62

20

EXAMPLE 39

3-(2-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

25

Analysis calculated for C₁₇H₁₃FO₄S
 C, 61.44; H, 3.94
Found: C, 61.13; H, 3.85

EXAMPLE 40

3-(4-Methylthiophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

30

¹H NMR (300 MHz, acetone-d₆) δ 8.0 (2H, d), 7.70 (2H, d), 7.35 (2H, d), 7.25 (2H, d), 5.35 (2H, s), 3.15 (3H, s), 2.55 (3H, s).

- 103 -

EXAMPLE 413-(3-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

- 5 ^1H NMR (300 MHz, CDCl_3) δ 7.93 (2H, d), 7.49 (2H, d), 7.35 (1H, m), 7.12 (3H, m), 5.18 (2H, s), 3.06 (3H, s).

EXAMPLE 42

- 10 3-(2-Chloro-6-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

- 15 ^1H NMR (300 MHz, acetone- d_6) δ 8.0 (2H, d), 7.70 (2H, d), 7.55-7.65 (1H, m), 7.40 (1H, d), 7.30 (1H, m), 5.60 (2H, s), 3.15 (3H, s).

EXAMPLE 43

- 20 3-(3-Bromo-4-methylphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

Analysis calculated for $\text{C}_{18}\text{H}_{15}\text{BrO}_4\text{S}$
 C, 53.08; H, 3.71
Found: C, 53.06; H, 3.83

25

EXAMPLE 44

- 3-(4-Bromo-2-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

- 30 Analysis calculated for $\text{C}_{17}\text{H}_{12}\text{BrFO}_4\text{S}$
 C, 49.65; H, 2.94
Found: C, 49.76; H, 3.00

- 104 -

EXAMPLE 453-(3,4-Dibromophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

5 ¹H NMR (300 MHz, acetone-d₆) δ 8.0 (2H, d), 7.80 (1H, d), 7.75 (3H, m), 7.25 (1H, d), 5.35 (2H, s), 3.15 (sH, s)

EXAMPLE 46

10 3-(4-Chloro-3-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

Analysis calculated for C₁₇H₁₂ClFO₄S
 C, 55.67; H, 3.30

15 Found: C, 55.45; H, 3.30

EXAMPLE 47

20 3-(4-Bromo-3-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

Analysis calculated for C₁₇H₁₂BrFO₄S
 C, 49.66; H, 2.94; S, 7.80

25 Found: C, 49.79; H, 3.01; S, 7.51

EXAMPLE 48

30 3-(4-Bromo-2-chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

Analysis calculated for C₁₇H₁₂BrClO₄S
 C, 47.74; H, 2.83; S, 7.50

Found: C, 47.92; H, 2.84; S, 7.42

- 105 -

EXAMPLE 493-(2-Naphthyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

5 Analysis calculated for C₂₁H₁₆O₄S
 C, 69.22; H, 4.43
 Found: C, 69.22; H, 4.46

EXAMPLE 50

10

3-(7-Quinoliny)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

 Analysis calculated for C₂₀H₁₅NO₄S
 C, 65.74; H, 4.14; N, 3.83
15 Found: C, 65.34; H, 4.40; N, 3.80
 M.S. (DCI, CH₄) calculated for M⁺, 365
 Found for M⁺+1, 366

EXAMPLE 51

20

3-(3,4-Dichlorophenyl)-4-(4-(aminosulfonyl)phenyl)-2-(5H)-furanone

¹H NMR (400 MHz, CD₃COCD₃) δ 7.92 (2H, dd), 7.64 (3H, dm), 7.60
25 (1H, dd), 7.32 (1H, dd), 6.70 (1H, bs), 5.38 (2H, s).

EXAMPLE 523-(3,4-Difluorophenyl)-4-(4-(aminosulfonyl)phenyl)-2-(5H)-furanone

30 ¹H NMR (400 MHz, CD₃COCD₃) δ 7.92 (2H, dd), 7.64 (2H, dd), 7.30-
 7.45 (2H, m), 7.22 (1H, m), 6.68 (2H, bs), 5.37 (2H, s).

- 106 -

EXAMPLE 53

3-(3-Chloro-4-methoxyphenyl)-4-(4-(aminosulfonyl)phenyl)-2-(5H)-
furanone

5

Analysis calculated for C₁₇H₁₄ClNO₅S
 C, 53.76; H, 3.72, N, 3.69

Found: C, 53.32; H, 3.84, N, 3.59

M.S. (DCI, CH₄) calculated for M⁺, 379

10

Found for M⁺+1, 380

EXAMPLE 54

3-(3-Bromo-4-methoxyphenyl)-4-(4-(aminosulfonyl)phenyl)-2-(5H)-
furanone

15

Analysis calculated for C₁₇H₁₄BrNO₅S
 C, 48.13; H, 3.33, N, 3.30

Found: C, 48.26; H, 3.40, N, 3.28

20

M.S. (DCI, CH₄) calculated for M⁺, 423

Found for M⁺+1, 424

25

30

- 107 -

WHAT IS CLAIMED IS:

1. A compound selected from the group consisting of:
- 5 (a) 3-(2,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (b) 3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (c) 3-(2,6-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- 10 (d) 3-(2,5-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (e) 3-(3,5-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- 15 (f) 3-(4-Bromophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (g) 3-(4-Methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (h) 3-(Phenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- 20 (i) 3-(2-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (j) 3-(2-Bromo-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (k) 3-(2-Bromo-4-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- 25 (l) 3-(4-Chloro-2-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (m) 3-(3-Bromo-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- 30 (n) 3-(3-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (o) 3-(2-Chloro-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (p) 3-(2,4-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,

- 108 -

- (q) 3-(3,4-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (r) 3-(2,6-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- 5 (s) 3-(3-Chloro-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (t) 3-(4-Trifluoromethylphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- 10 (u) 3-(3-Fluoro-4-methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (v) 3-(3-Chloro-4-methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (w) 3-(3-Bromo-4-methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- 15 (x) 3-(2-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (y) 3-(4-Methylthiophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- 20 (z) 3-(3-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (aa) 3-(2-Chloro-6-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (bb) 3-(3-Bromo-4-methylphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- 25 (cc) 3-(4-Bromo-2-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (dd) 3-(3,4-Dibromophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- 30 (ee) 3-(4-Chloro-3-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (ff) 3-(4-Bromo-3-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (gg) 3-(4-Bromo-2-chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,

- 109 -

- (hh) 3-(2-Naphthyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (ii) 3-(7-Quinoliny)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- 5 (jj) 3-(3,4-Dichlorophenyl)-4-(4-(aminosulfonyl)phenyl)-2-(2H)-furanone,
- (kk) 3-(3,4-Difluorophenyl)-4-(4-(aminosulfonyl)phenyl)-2-(2H)-furanone,
- 10 (ll) 3-(3-Chloro-4-methoxyphenyl)-4-(4-(aminosulfonyl)phenyl)-2-(2H)-furanone, and
- (mm) 3-(3-Bromo-4-methoxyphenyl)-4-(4-(aminosulfonyl)phenyl)-2-(2H)-furanone, or a pharmaceutically acceptable salt thereof.
2. A compound selected from the group consisting of:
- 15 (a) 3-(2,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (b) 3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- 20 (c) 3-(2,6-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (d) 3-(2,5-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (e) 3-(3,5-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- 25 (f) 3-(4-Bromophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (g) 3-(4-Methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (h) 3-(Phenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- 30 (i) 3-(2-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (j) 3-(2-Bromo-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,


- (k) 3-(2-Bromo-4-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-
2-(5H)-furanone,
- (l) 3-(4-Chloro-2-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-
2-(5H)-furanone,
- 5 (m) 3-(3-Bromo-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-
2-(5H)-furanone,
- (n) 3-(3-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-
furanone,
- (o) 3-(2-Chloro-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-
10 2-(5H)-furanone,
- (p) 3-(2,4-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-
(5H)-furanone,
- (q) 3-(3,4-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-
(5H)-furanone,
- 15 (r) 3-(2,6-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-
(5H)-furanone,
- (s) 3-(3-Chloro-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-
2-(5H)-furanone,
- (t) 3-(4-Trifluoromethylphenyl)-4-(4-(methylsulfonyl)phenyl)-
20 2-(5H)-furanone,
- (u) 3-(3-Fluoro-4-methoxyphenyl)-4-(4-(methylsulfonyl)-
phenyl)-2-(5H)-furanone,
- (v) 3-(3-Chloro-4-methoxyphenyl)-4-(4-(methylsulfonyl)-
phenyl)-2-(5H)-furanone,
- 25 (w) 3-(3-Bromo-4-methoxyphenyl)-4-(4-(methylsulfonyl)-
phenyl)-2-(5H)-furanone,
- (x) 3-(2-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-
furanone,
- (y) 3-(4-Methylthiophenyl)-4-(4-(methylsulfonyl)phenyl)-2-
30 (5H)-furanone,
- (z) 3-(3-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-
furanone,
- (aa) 3-(2-Chloro-6-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-
2-(5H)-furanone,
- 35 (bb) 3-(3-Bromo-4-methylphenyl)-4-(4-(methylsulfonyl)-
phenyl)-2-(5H)-furanone,

- (cc) 3-(4-Bromo-2-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-
2-(5*H*)-furanone,
- (dd) 3-(3,4-Dibromophenyl)-4-(4-(methylsulfonyl)phenyl)-2-
(5*H*)-furanone,
- 5 (ee) 3-(4-Chloro-3-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-
2-(5*H*)-furanone,
- (ff) 3-(4-Bromo-3-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-
2-(5*H*)-furanone,
- 10 (gg) 3-(4-Bromo-2-chlorophenyl)-4-(4-(methylsulfonyl)-phenyl)-
2-(5*H*)-furanone,
- (hh) 3-(2-Naphthyl)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-
furanone,
- (ii) 3-(7-Quinoliny)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-
furanone,
- 15 (jj) 3-(3,4-Dichlorophenyl)-4-(4-(aminosulfonyl)phenyl)-2-
(2*H*)-furanone,
- (kk) 3-(3,4-Difluorophenyl)-4-(4-(aminosulfonyl)phenyl)-2-(2*H*)-
furanone,
- 20 (ll) 3-(3-Chloro-4-methoxyphenyl)-4-(4-(aminosulfonyl)-
phenyl)-2-(2*H*)-furanone,
- (mm) 3-(3-Bromo-4-methoxyphenyl)-4-(4-(aminosulfonyl)-
phenyl)-2-(2*H*)-furanone, and
- (nn) 5,5-Dimethyl-3-(3-fluorophenyl)-4-(4-
methylsulfonylphenyl)-2-(5*H*)-furanone, or a
25 pharmaceutically acceptable salt thereof.


3. A compound selected from the group consisting of:

- 112 -


5



10




15




20


25




30




4. A compound selected from the group consisting of:



10




20




30


- 114 -



- 115 -



- 116 -



- 117 -

5 5. A compound according to Claim 1 which is
 3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-
 (5*H*)-furanone, or
 a pharmaceutically acceptable salt thereof.

 6. A compound according to Claim 1 which is
 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-furanone, or
 a pharmaceutically acceptable salt thereof.

10 7. A pharmaceutical composition for treating an
 inflammatory disease susceptible to treatment with an non-steroidal anti-
 inflammatory agent comprising: a non-toxic therapeutically
 effective amount of a compound according to Claim 1, 2, 3,
15 4, 5 or 6 and a pharmaceutically acceptable carrier.

 8. A pharmaceutical composition for treating
 cyclooxygenase mediated diseases advantageously treated by an active
 agent that selectively inhibits COX-2 in preference to COX-1
20 comprising: a non-toxic therapeutically effective amount
 of a compound according to Claim 1, 2, 3, 4, 5 or 6 and
 a pharmaceutically acceptable carrier.

 9. A method of treating an inflammatory disease
25 susceptible to treatment with an non-steroidal anti-inflammatory agent
 comprising:
 administration to a patient in need of such treatment of a non-toxic
 therapeutically effective amount of a compound according to Claim 1 and
 a pharmaceutically acceptable carrier.

30 10. A method of treating cyclooxygenase mediated
 diseases advantageously treated by an active agent that selectively
 inhibits COX-2 in preference to COX-1 comprising:
 administration to a patient in need of such treatment of a non-toxic
 therapeutically effective amount of a compound according to Claim 1.

SUBSTITUTE SHEET

- 118 -

11. A pharmaceutically acceptable salt of a compound of claim 1, 2, 3, 4, 5, or 6.

12. A compound as defined in claim 1, 2, 3, 4, 5 or 6, or a pharmaceutically acceptable salt thereof, for use in the treatment of cyclooxygenase mediated diseases advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1.

13. A compound as defined in claim 1, 2, 3, 4, 5 or 6, or a pharmaceutically acceptable salt thereof, for use in treating an inflammatory disease susceptible to treatment with a non-steroidal anti-inflammatory agent.

14. Use of a compound of claim 1, 2, 3, 4, 5 or 6, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of an inflammatory disease susceptible to treatment with a non-steroidal anti-inflammatory agent.

15. Use of a compound of claim 1, 2, 3, 4, 5 or 6, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cyclooxygenase mediated diseases advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1.

16. A non-steroidal anti-inflammatory pharmaceutical composition comprising an acceptable non-toxic, anti-inflammatory amount of a compound of claim 1, 2, 3, 4, 5 or 6, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.

17. A selective COX-2 inhibitor pharmaceutical composition comprising an acceptable, non-toxic,

- 119 -

therapeutically effective amount of a compound of claim
1, 2, 3, 4, 5 or 6, or a pharmaceutically acceptable
salt thereof, in association with a pharmaceutically
5 acceptable carrier.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 94/00688

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D307/58 C07D309/32 C07C311/15 C07C309/73 A61K31/34
A61K31/365 A61K31/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO,A,95 00501 (MERCK FROSST CANADA) 5 January 1995	1-17
X	see whole document see examples 9-56 ---	1
P,X	WO,A,94 15932 (SEARLE) 21 July 1994 see compounds 16, Scheme IV on page 32 and example 13, step 5 ---	1-17
E	WO,A,95 05376 (WARNER-LAMBERT COMPANY) 23 February 1995 see claim 1 ---	1
Y	WO,A,91 16055 (ALLERGAN) 31 October 1991 see page 1, line 5-8; claim 1 ---	1-17
	--- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
 "&" document member of the same patent family

Date of the actual completion of the international search

21 April 1995

Date of mailing of the international search report

- 2. 05. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+ 31-70) 340-3016

Authorized officer

Lauro, P

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 94/00688

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO,A,91 19708 (FUJISAWA) 26 December 1991 see examples see page 1 - page 2 ---	1-17
Y	EP,A,0 388 909 (FUJISAWA) 26 September 1990 see page 9, line 7-29; claim 1 -----	1-17

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 94/00688

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9500501	05-01-95	AU-B- 6967494	17-01-95
WO-A-9415932	21-07-94	AU-B- 6027694	15-08-94
WO-A-9505376	23-02-95	NONE	
WO-A-9116055	31-10-91	AU-A- 7559691 EP-A- 0524979	11-11-91 03-02-93
WO-A-9119708	26-12-91	AU-A- 7973191 CN-A- 1059142 EP-A- 0593761 JP-T- 6501919	07-01-92 04-03-92 27-04-94 03-03-94
EP-A-388909	26-09-90	AU-B- 631169 AU-A- 4768790 CA-A- 2007133 EP-A- 0377457 JP-A- 3014569 JP-A- 3027370 US-A- 5145860 US-A- 5217971 US-A- 5229386 CA-A- 2012716	19-11-92 12-07-90 05-07-90 11-07-90 23-01-91 05-02-91 08-09-92 08-06-93 20-07-93 22-09-90

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.